Eupraxia Pharmaceuticals shares are trading higher after the company announced data from its Phase 1b/2a RESOLVE trial showing 'tolerability and extended signals of potential efficacy out to 24 weeks without meaningful side effects.'
$EPRX
Pharmaceuticals and Biotechnology
Health Care
Eupraxia Pharmaceuticals shares are trading higher after the company announced data from its Phase 1b/2a RESOLVE trial showing 'tolerability and extended signals of potential efficacy out to 24 weeks without meaningful side effects.'